
11/	a plus sign (+) in this box	_
—		



SUBSTITUTE PTO/SB/05 Approved for use through 10/31/2002.

nark Office: U.S. DEPARTMENT OF COMMERCE

UTILITY ATENT APPLICATION TRANSMITTAL

Attorney Docket No. AFD 490

First Inventor or Application Identifier Harvey A. Schwertner

BILIRUBIN TESTS AS RISK PREDICTORS FOR CANCER Title MORTALITY, RHEUMATOID ARTHRITIS, GILBERT'S SYNDROME AND ALL-CAUSE MORTALITY (Only for new non-provisional applications under 37 C.F.R. § 1.53(b)) Express Mail Label No. Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: **Box Patent Application** See MPEP chapter 600 concerning utility patent application contents Washington, DC 20231 7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) X *Fee Transmittal Form (e.g., PTO/SB/17) Nucleotide and/or Amino Acid Sequence Submission Applicant claims small entity status 2. (if applicable, all necessary) (See 37 CFR 1.27) Computer Readable Form (CRF) [Total Pages Specification (Preferred arrangement set forth below) Specification Sequence Listing on: - Descriptive title of the invention - Cross Reference to Related Applications CD-ROM or CD-R (2 copies); or - Statement Regarding Fed sponsored R&D ii. Paper - Reference to sequence listing, a table, or a computer program listing appendix Statements verifying identity of above copies - Background of the Invention - Brief Summary of the Invention **ACCOMPANYING APPLICATION PARTS** - Detailed Description 9. Assignment Papers (cover sheet & document(s)) - Claim(s) - Abstract of the Disclosure 37 CFR 1.373(b) Statement Power of Attorney 10. English Translation Document (if applicable) Drawing(s) (35 U.S.C. 113) [Total Sheets 11. Information Disclosure Copies of IDS 545 Oath or Declaration [Total Pages 12. Statement (IDS) PTO-1449 Citations a. Newly executed (original or copy) 13. **Preliminary Amendment** Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed) Return Receipt Postcard (MPEP 503) (should be itemized) 訓練 Certified Copy of Priority Document(s) **DELETION OF INVENTOR(S)** Signed statement attached deleting inventor(s) Request and Certification under 35 U.S.C. 122 16. X ij named in the prior application, see 37 CFR (b)(2)(B)(i). Applicant must attach for PTO/SB/35 or its 1.63(d)(2) and 1.33(b). 13 equivalent. 17. X Other: Certificate of 37 CFR 1.10 Express Mailing Application Data Sheet. See 37 CFR 1.76 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76 of prior application No: ☐ Divisional ☐ Continuation in Part (CIP) ☐ Continuation Prior application information: Examiner Group / Art Unit F r CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5B, is considered to be a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. CORRESPONDENCE ADDRESS or L Correspondence address below (Insert Cus. FREDRIC L. SINDER Name AFMC LO/JAZ **BLDG 11, ROOM 100** Address 2240 B STREET 45433-7109 WRIGHT-PATTERSON AFB OH Zip Code State City (937) 255-2838 (937) 255-3733 Fax Telephone Country U.S.A.

Name (Print / Type)	FREDRIC L. SINDER	Registration No. (Attorney / Agent)	28,475
Signature	De Si	Date	9 Nov 01

PE FEE TRANSPITTAL							emplete if Known							
1/0	स्राधा			Application Number										
KOV 0 9 2				Filing Dat										
		Named	Invent	or	Han	vey A. Schwertr	ner							
PATENT & TO	Examiner Name													
	Group Art Unit													
TOTAL AM	OUNT OF PA	YMENT		(\$)	740.00	Attorn	ey Docl	ket Nur	nber	AFD	490	3		
	FEE CALCULATION (continued)													
1. X The fees	3. ADDITIONAL FEES													
Deposit Account Number	AF 01-0465						Large Entity Fee (\$)	Small Entity Code	Small Entity Fee (\$)	ı	Fee Description	Fee Paid		
Deposit Account Name	Dep	oartmen	t of the A	ir Forc	е	105	130	205	65	Surchar	ge - late filing fee or oath			
Charge A under 37	ny Additional Fee F CFR 1.16 and 1.17			nt claims s See 37 CF	mall entity R 1.27	127	50	227	25		ge - late provisional filing over sheet			
2. □ Paym	nent Enclosed	l:				139	130	139	130	-	glish specification			
☐ Check	☐ Credit Ca		Money Ord	er 🗆	Other	147	2,520	147	2,520	reexami				
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		CALCUL	ATION			112	920*	112	920*	to Exam	ting publication of SIR prior iner Action			
1. BASIC FILIN						113	1,840*	113	1,840*	Request Examine	ting publication of SIR after er action			
	e Entity Sm. Entity ee (\$) Fee Code		y Fee Desc	cription	Fee Paid	115	110	215	55	Extension	on for reply within first month			
1 1	740 201	370	Utility Fili	•	740	116	400	216	200	Extension month	on for reply within second			
22.000	330 206	165	Design F	iling Fee		117	920	217	460	Extension month	on for reply within third			
7	510 207	255	Plant Fili	ng Fee		118	1440	218	720	Extension month	on for reply within fourth			
108	740 208	370	Reissue	Filing Fee		119	320	219	160	Notice o	of Appeal			
	160 214	80	Provision Fee	al Filing		120	320	220	160	Filing a	brief in support of an appeal			
l i			. 00			121	280	221	140	Request	t for oral hearing			
# # # # # # # # # # # # # # # # # # #		SL	BTOTAL (1)	(\$)	740.00	138	1,510	138	1,510	Petition proceed	to institute a public use ling			
+						140	110	240	55	•	Petition to revive – unavoidable			
2. ÉXTRA CLAI	M FEES	E		e from	Fee Paid	141	1,280	241	640	Petition	Petition to revive - unintentional			
Total Claims		- 20** =		18 =	0	142	1,280	242	640	Utility is	sue fee (or reissue)			
Independent claims	s	- 3=	0 ×	84 =	0	143	440	243	220	•	issue fee			
Mülliple dependent	t claims					144	620	244	310	Plant iss				
, '						122	130	122	130		s to the Commissioner			
Large Entity	Small E	intity				123	50	123	50	1.17(q)	ing fee under 37 CFR			
Fee Code Fee	(\$) Fee code	Fee (\$) F	ee Description			126	180	126	180	Disclosu	sion of Information ure Statement			
103 1	8 203	9 (Claims in exce	ss of 20		581	40	581	40		ng each patent assignment perty (times # of properties)			
102 8	34 202	42 lı	ndependent cl	aims in ex	cess of 3	146	740	246	370		submission after final n (37 CFR §1.129(a))			
104 2	70 204	135 N	Aultiple depen	dent claim	1	149	740	249	370	For each	h additional invention to be ed (37 CFR §1.129(b))			
109 8	34 209		*Reissue inde	pendent c	laims over	179	740	279	370		t for Continued Examination			
110 1	18 210		riginal patent *Reissue clair	ns in exce	ss of 20 and					(NUE)				
''		_ 0	ver original pa	atent		Other fee	(specify) _					<u> </u>		
SUBTOTAL (2)									SL	JBTOTAL	- (3) \$ <i>O</i>			
·· or r	*Reduce	d by Basic Fi	iling Fee Pa	iid										
SUBMITTED BY Typed or								Comple	ete (if appl					
Printed Name	FRED	RIC L. S	SINDER		Registration. N	0.	28,4	<i>75</i>	Teleph	one	(937) 255-2	2838		
Signature	Date 9 Nov 01								<u>t</u>					
Typed or Printed Name					Registration. N	о.			Teleph	ione				
Signature									Date					

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Harvey A. Schwertner et al

Group Art Unit:

Serial No.:

(AFD 490)

Examiner:

Filed:

For:

BILIRUBIN TESTS AS RISK PREDICTORS FOR CANCER

MORTALITY, RHEUMATOID ARTHRITIS, GILBERT'S

SYNDROME AND ALL-CAUSE MORTALITY

CERTIFICATE OF MAILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

	<u>S</u>
Date of Deposit: November 9, 2001	

I certify that this patent application is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above from AFMC LO/JAZ, Bldg 11, Room 100, 2240 B Street, Wright-Patterson Air Force Base, Ohio 45433-7109 and is addressed to Box Patent Application, Assistant Commissioner for Patents, Washington DC 20231.

FREDRIC L. SINDER, Reg. No. 28,475 Attorney for Applicants

PISI

FL Sinder 937/255-2838

		Substitute PTO/SE	1, (11-11)	
C	omple	te if Known		ı
				1
				0
nt	or	Harvey A. Schwertn	er	
un	nber	AFD 490		
	LCULA			
<u></u>	ES Small			
•	Entity Fee (\$)	Fee Description	Fee Paid	
	or.	Surcharge - late filing fee or oath		
	65			
	25	Surcharge - late provisional filing fee or cover sheet		
	130	Non-English specification		
	2,520	 For filing a request for ex parte reexamination 		
	920*	Requesting publication of SIR prior to Examiner Action		
	1,840*	Requesting publication of SIR after Examiner action		
	55	Extension for reply within first month		
	200	Extension for reply within second month		
	460	Extension for reply within third month		
	720	Extension for reply within fourth month		
	160	Notice of Appeal		
	160	Filing a brief in support of an appeal		
	140	Request for oral hearing		
	1,510	Petition to institute a public use proceeding		
l	55	Petition to revive - unavoidable		
	640	Petition to revive - unintentional		
!	640	Utility issue fee (or reissue)		
1	220	Design issue fee		

Date

Signature

	LEE II	CVIA		ML							<u> </u>			
			Application Num											
			Filing Dat											
	vision.		First	Nam d	Inv nt	or	Harve	Harvey A. Schwertner						
			Exam	iner Na	me									
						Grou	Art Un	it				e.		
TOTAL AMO	(\$)	740.00	Attorr	Attorney Docket Number AFD 490										
TOTALA		F	EE CA	LCULA	TION	(continued)								
	Commissioner i	is hereby a			dicated	0.45	DITION	IAI EE	EC					
fees and credit any overpayments to:							3. ADDITIONAL FEES Large Large Small Small							
Deposit Account Number		AF 01-0465						Entity Code	Entity Fee (\$)	Fee	e Description	Fee Paid		
Deposit Account Name	De	e	105	130	205	65	Surcharge	- late filing fee or oath						
	ny Additional Fee CFR 1.16 and 1.1			cant claims s s. See 37 Cl		127	50	227	25	Surcharge	- late provisional filing			
						139	130	139	130		h specification			
	ent Enclose	_	l Manay C	order 🗖	Other	147	2,520	147	2,520	- For filing a reexaminat	request for ex parte			
☐ Check	☐ Credit C		Money C	, dei L	Oniei	112	920*	· 112	920°	Requesting	publication of SIR prior			
1. BASIC FILIN		UALUU		· ·		113	1,840*	113	1,840°		publication of SIR after			
	Entity Sm. Enti	ity · Sm. En	tity		Fee Paid	115	110	215	55	Examiner a Extension (iction for reply within first month			
Fee Code Fe	e (\$) Fee Cod	·		escription	7.0	4		216	200		for reply within second			
106	740 201	370	-	Filing Fee	740	. 116	.400		460	month Extension	for reply within third	<u> </u>		
106	30 206 165 Design Filing Fee					117	920	217		month Extension	for reply within fourth			
107	510 207	255	Plant	Filing Fee		118	1440	218	720	month				
	740 208	370		ue Filing Fee	<u> </u>	119	320	219	160	Notice of A				
VERT COMPARED AND	160 214	80	Provis Fee	sional Filing	_	120	320	220	160	Filing a bri	ef in support of an appeal			
FM.						121	280	221	140		or oral hearing			
		(SUBTOTAL	(1) (\$)	740.00	138	1,510	138	1,510	Petition to proceeding	institute a public use			
ļ. ļ		•		سكند		140	110	- 240	55	Petition to	revive – unavoidable			
2. EXTRA CLAII	M FEES		Extra	Fee from	Fee Paid	141	1,280	241	640	Petition to	revive - unintentional	ļ		
TotaPClaims		- 20** =	0 ×	below =	0	142	1,280	242	640	Utility issu	e fee (or reissue)			
Independent claims	,	. 3=	0 ×	84 =	0	143	440	243	220	Design iss	sue fee			
Multiple dependent	<u> </u>	ا ل				144	620	244	310	Plant issue	e fee			
14						122	130	122	130	Petitions t	o the Commissioner	1 .		
Laura Entitu	Small	Entity				123	50	123	50	Processin 1.17(q)	g fee under 37 CFR			
Large Entity Fee Code Fee	(\$) Fee code	Fee (\$)	Fee Descript	ion		126	180	126	180	Submissio	on of Information			
	•••	9	•	xcess of 20		581	40	581	40	Recording	e Statement geach patent assignment			
										Filing a su	rty (times # of properties) ubmission after final			
102 . 8	34 202	42	·	nt claims in e		146	740	246	370		37 CFR §1.129(a)) additional invention to be			
104 2	70 204	135		pendent clair		149	740	249	370	examined	(37 CFR §1.129(b)) or Continued Examination	<u> </u>		
109 8	34 209	42	original pat			179	740	279	370	(RCE)	or Communic Examination	-		
110	18 210	9	**Reissue over origina		ess of 20 and	Other f	ee (specify)					L		
				S	UBTOTAL	(3) \$	o ·							
** or number previously paid, if greater, For Reissues, see below *Reduced by Basic Filing Fee Paid														
SUBMITTED BY								Comp	lete (if app					
Typed or Printed Name	FRE	DRIÇ L	. SINDE	R	Registration.	No.	28,4	475	Telep	phone	(937) <u>25</u> 5-	2838		
Signature -	Signature Date 9 Nov 01										01			
Typed or Printed Name					Registration.	No			Telep	ohone				

REQUEST AND CERTIFICATION UNDER 35 U.S.C. 122(b)(2)(B)(i)

First Named Inventor

Harvey A. Schwertner

Title

BILIRUBIN TESTS AS RISK PREDICTORS FOR CANCER MORTALITY, RHEUMATOID ARTHRITIS, GILBERT'S SYNDROME AND ALL-CAUSE MORTALITY

Atty Docket Number

AFD 490

I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 1.22(b).

9 N N 0 /

Signature

FREDRIC L. SINDER

Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and be submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant must notify the United States Patent and Trademark office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. Failure to do so will result in abandonment of this application (35 US.C. 122(b)(2)(B)(iii)).